Fluoropyrimidines, including 5-fluorouracil and capecitabine, induce cardiovascular toxicities such as angina and coronary spasm with an incidence ranging from 1% to 19% and a mortality rate of 2.2% to 13.3%.
Highlights the need for standardized management and randomized clinical trials to address cardiovascular toxicities associated with fluoropyrimidine cancer therapies.
OPINION STATEMENT: Fluoropyrimidine (FP) is used to treat a wide range of cancers; however, it is associated with drug-induced vascular toxicity, as well as angina pectoris and coronary spasm. FP has been administered for many years, although the incidence, mechanisms, and appropriate methods for managing its associated cardiovascular toxicities have not been clarified, and the management of these complications has not been standardized. This lack of evidence is not limited to FP. Many trials of anticancer agents have been conducted, excluding patients with heart diseases. Hence, there is a paucity of epidemiological data on cardiovascular adverse events caused by anticancer agents. There have been remarkable improvements in cancer treatment in recent years, with consequent improvements in prognosis. In this context, new cardiovascular toxicities related to new drugs have emerged. We are now compelled to respond to cardiovascular adverse events despite the lack of evidence regarding optimal management. The result has been establishment and rapid maturation of the new academic field of cardio-oncology. Despite the relative lack of evidence, we must review small pieces of evidence that have accumulated to date and make the utmost efforts to provide patients with effective evidence-based medical care. Simultaneously, we urgently need randomized clinical trials to build strong evidence.
Shiga et al. (Thu,) conducted a review in Cancer. Fluoropyrimidines (5-Fluorouracil, Capecitabine) was evaluated. Fluoropyrimidines, including 5-fluorouracil and capecitabine, induce cardiovascular toxicities such as angina and coronary spasm with an incidence ranging from 1% to 19% and a mortality rate of 2.2% to 13.3%.